UnitedHealthcare Faces DOJ Investigation Over Medicare Billing Practices Amid Stock Decline
UnitedHealthcare is under investigation by the DOJ for potential fraud in its Medicare Advantage billing, as its stock suffers significant losses.
Subscribe to unlock this story
We really don't like cutting you off, but you've reached your monthly limit. At just $5/month, subscriptions are how we keep this project going. Start your free 7-day trial today!
Get Started
Those developments in recent days extend a tumultuous past year for its parent company, UnitedHealth Group, marked by the killing of a top executive, a costly cyberattack against its subsidiary and high medical costs in its insurance arm.
CNBC·2M·ReliableThis source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.CenterThis outlet is balanced or reflects centrist views.
UnitedHealth has faced particularly intense scrutiny, at least in the public eye, since the chief executive of its insurance company, Brian Thompson, was executed in Midtown Manhattan in December.
DOJ launches probe into UnitedHealth’s Medicare billing practices after investigative reports
New York Post·2M·Mostly ReliableThis source is generally reliable but sometimes includes opinion, propaganda, or minor inaccuracies.Leans RightThis outlet slightly leans right.
A raft of studies now show the program probably costs taxpayers billions more each year.
US justice department opens civil fraud investigation into UnitedHealthcare
The Guardian·2M·ReliableThis source consistently reports facts with minimal bias, demonstrating high-quality journalism and accuracy.Leans LeftThis outlet slightly leans left.
Summary
The DOJ is investigating UnitedHealthcare for alleged fraudulent Medicare Advantage billing practices, examining whether it inflated payments through questionable diagnoses. Recent reports link the scrutiny to the company's larger struggles, including declining stock value and employee buyouts. Claims suggest that UnitedHealthcare's practices have led to excessive Medicare costs and increased patient access issues. The firm's response labels the claims as misinformation, while analysts predict a slow resolution of the probe, emphasizing its extensive involvement in the healthcare sector.
Perspectives
No center-leaning sources available for this story.